If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be ...

Background Antimicrobial resistance (AMR) is a growing global health crisis and is particularly relevant to people living ...

Objective Long-term azithromycin treatment effectively prevents acute exacerbations of chronic obstructive pulmonary disease ...

Pulmonary rehabilitation has established itself as a vital and core therapy for people with chronic lung disease. Significant improvements are seen in several patient outcomes, for the thousands ...

We present a 33-year-old woman with anti-U1 ribonucleoprotein antibody positive mixed connective tissue disease (MCTD) since the age of 13. Predominant features were of inflammatory arthritis, Raynaud ...

A pillar of the WHO End TB Strategy is targeted latent tuberculosis infection (LTBI) testing to identify persons who would benefit from TB preventive treatment (TPT).1 The WHO recommends the ...

Background Idiopathic pulmonary fibrosis (IPF) is characterised by damage to the epithelial layer, closely associated with the alveolar basement membrane (BM). We aimed to investigate how type IV ...

Background Hospitalisation for acute exacerbations of COPD is associated with high risk of readmission. However, no tool has been validated to stratify patients at discharge for risk of readmission.

Background Prior work suggests different interstitial lung diseases (ILDs) that share the radiological usual interstitial pneumonia (UIP) pattern have an overall worse prognosis. However, ...

Background Minimising hypoxaemia during submaximal walking tests has a positive effect on exercise capacity and dyspnoea in patients with chronic obstructive pulmonary disease (COPD) on long-term ...

Background The diagnosis and management of pneumonia is often challenging due to its overlapping clinical presentations with other respiratory illnesses, low pathogen identification rates, and slow ...

In this issue of Thorax , Czepiel et al report the results of a double-blind randomised controlled trial of an oral agent, hymecromone, in patients with pulmonary hypertension (PH).1 The authors ...